Veldig spennende @larosaleda
Det viser hvor lite som skiller mellom svært godt og vansinnigt godt! Det blir veldig spennende å følge modningen her.
Kan du forklare hva du mener med “sensurert på 19 nå er sensurert på 20”?
Såvidt jeg ser er det ingen ufullstendig observerte levetider for CR-pasienter?
Orano med ser ut til å være en del av Orano group…
http://www.orano.group/en/group/orano-europe
3 Likes
From ASH with love
Posteren med Nano og oranomed
Pb212-NNV-003
http://www.nordicnanovector.com/sites/default/files/link-documents/poster-ash-2018-oranomed-web.pdf
Edit. Og her er linken til abstractet.
4422
Amal Saidi, PhD 1*, Astri Maaland2*, Julien Torgue, PhD1*, Helen Heyerdahl, PhD2* and Jostein Dahle, PhD3*
1Orano Med, Plano, TX
2Research and Development, Nordic Nanovector, Oslo, Norway
3Research & Development, Nordic Nanovector
3 Likes
Og her er børsmeldingen…
04/12-2018 03:01:12: (NANO) Nordic Nanovector: Additional preclinical studies with CD37-targeting radioimmunotherapies for B-cell malignancies presented at ASH
Oslo, Norway, 4 December 2018
Nordic Nanovector ASA (OSE: NANO) notes that two new poster presentations from
…Vis børsmeldingen
preclinical studies with CD37-targeting radioimmunotherapies were made at the
60th American Society of Hematology (ASH) Annual Meeting & Exposition (1-4
December 2018 in San Diego, CA, USA). These posters were presented in addition
to the results of the Phase 1/2 trial of Betalutin® (177Lu-satetraxetan
-lilotomab) in patients with relapsed/refractory indolent non-Hodgkin’s lymphoma
- see separate announcement.
The posters are as follows:
Abstract 4422
Abstract title:
Targeted Alpha Therapy with 212Pb-NNV-003 for the Treatment of CD37 Positive B
-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)Authors:
A. Saidi et al.
This poster describes results from a research collaboration to develop a novel
CD37-targeting alpha therapy for B-cell malignancies and the results noted in
the abstract were previously announced on 1 November 2018. The research
collaboration was established in June 2015 with Orano Med (formerly known as
AREVA Med) to develop and investigate a next-generation targeted alpha therapy,
comprising Nordic Nanovector’s chimeric anti-CD37 antibody (NNV003) and lead-212
(212Pb), for the treatment of B-cell malignancies.The preclinical studies investigated the dose-dependent efficacy and
tolerability of 212Pb-NNV003 in human cell and mouse models of chronic
lymphocytic leukaemia (CLL) and Burkitt’s lymphoma (a type of non-Hodgkin’s
lymphoma, NHL). In the studies, 212Pb-NNV003 was found to be well tolerated and
led to a 90-100% survival rate in mouse models of CLL and NHL.Abstract 1371
Abstract title:
Cell Cycle Kinase Inhibitors Potentiate the Effect of 177lu-Lilotomab
Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell LinesAuthors:
G.E. Rødland et al.
The poster describes results from a preclinical study aimed at identifying
possible drug combinations involving Betalutin® in two aggressive,
radioimmunotherapy-resistant diffuse large B-cell lymphoma (DLBCL) cell lines.
The study identified cell cycle kinase inhibitors as promising partners for
combination treatment of aggressive DLBCL with Betalutin®, warranting further
exploration in preclinical models.Both abstracts are available at http://www.hematology.org/Annual-Meeting/ and
the posters have been published on the Nordic Nanovector website -
http://www.nordicnanovector.com/what-we-do/scientific-publications/scientific
-postersAbout ASH
The ASH annual meeting is the premier event for scientific exchange in the field
of haematology, attracting more than 20,000 attendees from all over the world.
Typically, more than 5,000 scientific abstracts are submitted each year, and
more than 3,000 abstracts are accepted for oral and poster presentations through
an extensive peer review process.For further information, please contact:
IR enquiries
Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 638 9571
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 28.7 billion by 2026. Nordic Nanovector intends to retain
marketing rights and to actively participate in the commercialisation of
Betalutin® in core markets. Further information can be found at
www.nordicnanovector.comForward-looking statements
This press release contains certain forward-looking statements. These
statements are based on management’s current expectations and are subject to
uncertainty and changes in circumstances, since they relate to events and depend
on circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector’s business, financial condition and results
of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”,
“estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”,
“should”, “projects”, “targets”, “will”, “would” or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector’s
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector’s product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector’s potential market and
industry, Nordic Nanovector’s freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.This information is subject to a duty of disclosure pursuant to Section 5-12 of
the Securities Tradinhttp://www.netfonds.no/quotes/release.php?id=20181204.OBI.20181204S3
1 Like
Nok et bra resultat for Nano! Lover ikke bra for kursutviklingen 
Tumor uptake approach and can exceed 20% of injected dose per gram (%ID/g) by 24
hours in both CD37 positive tumors
212Pb-NNV003 presents a favorable toxicity profile with a reversible and recoverable effect
on body weight and platelet counts
A single 212Pb-NNV003 administration resulted in a significantly increased life expectancy.
The 10, 15 and 20µCi 212Pb-NNV003-treated groups did not reach a median survival at
study termination, 200 days post-treatment
The results of preclinical studies suggest that TAT using 212Pb-NNV003 is a safe and
effective method for the treatment of CD37 positive CLL and NHL
Nå må nano hente penger, eller partner, så de kan få fart på pipelinen sin! Det kan være med å øke oppkjøpverdien vesentlig.
Er det bare på min mobil at overskriftene i pdfen har så liten skrift at det nesten er usynlig?
Overskriften har fått betalutin, og er derfor snart helt borte.
6 Likes
Nei, grafene hadde hysterisk liten skrift. Dårlig utformet poster
Får sjekke om 9mnd 
Pressemelding fra Roche ifm ASH med hovedpunkter:
Basel, 03 December 2018
Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
- Polatuzumab vedotin in combination with MabThera/Rituxan (rituximab) plus bendamustine more than doubled overall survival, compared to MabThera/Rituxan plus bendamustine alone in the phase Ib/II GO29365 study
- Polatuzumab vedotin has the potential to provide a promising new treatment option at first relapse
- Results from the GO29365 study, the first and only randomised study to suggest a survival benefit for patients not eligible for a haematopoietic stem cell transplant, will be submitted to health authorities around the world for approval consideration
Studien viser Roche sitt arbeid for å gjøre kombinasjonsbehandling med Rituximab mer effektiv. Iflg studien OR doblet da Polatuzumab (anti-CD79b ADC) ble tilsatt en kombinasjon med Rituximab og cellegift. Hvis/når dette kommer på markedet (de har allerede BTD/ODD i USA og PRIME/ODD i EU) later det til å bedre behandlingstilbudet av R/R DLBCL.
a) Vil ikke dette ta vekk noe av markedspotensialet for Betalutin for denne indikasjonen (slik det forskes på i Lymrit 31-05 studien)?
b) Vil denne utviklingen av Polatuzumab (anti-CD79b) utgjøre en trussel mot Lilotomab/Betalutin (som er anti-CD37)?
2 Likes
Folk som har respons, vil stort sett over tid likevel få tilbakefall beklageligvis, så at den begrenser markedet er ikke så sikkert sånn sett. Hva gjelder markedspotensial for Betalutin i DLBCL, så har vi ikke efficacy-data overhodet enda, så vi har lite å jobbe fra i den sammenheng. Dersom det er en mer krevende behandling for pasientene, vil det være deler av markedet de ikke når ut til og således ikke vil konkurrere med Betalutin om.
4 Likes
Huff, de kunne trengt et kurs i poster-produksjon. Ser ut som om den originale font-typen i figurene har blitt byttet ut i pdf’en. Typisk sånn som kan skje under hastverk. Det er jo egentlig veldig synd ettersom innholdet i grafene er såpass interessant!
I tillegg ser det ut til at fargekodingen (for de ulike treatment doses) ikke er konsekvent fra figur til figur. I kombinasjon med forferdelig font-type/størrelse er dette svært uheldig. De burde kanskje vurdere litt bedre kvalitetskontroll på postere i forkant av konferanser.
1 Like
Skulle gjerne stilt ledergruppa i Nano spørsmålet, “..og hvordan synes dere selv det gikk på ASH?”, med rynkede øyenbryn og skarp stemme.
En - 1 - tweet fikk vi om NANO på #ASH18 som ikke kom fra børstjenester eller undertegnede…
2 Likes
Har Nano twitterkonto?
Rita Dege har, men that’s it
Personlig har jeg ikke brukt Twitter noe særlig, har konto men ikke brukt på siste 5år, så jeg vet ikke hvor aktuelt det er med bra omdømme for NANO her?
men selvfølgelig er jo god PR og blest rundt NANO gode greier det.
Tror ikke det er verdt tid og energi å fokusere på det engang, jeg personlig har tunnelsyn på resultat som blir lagt frem og om dette er godt nok til å komme med kommersielt produkt.
Jeg kan være enig i at selskaper som foreksempel FUN og GIG, kan ha en slags lesning ut av Twitter/sosiale medier da dem apelerer til en helt annen gruppe mennesker/brukere.
NANO har ett meget bra produkt, med en meget profesjonell og erfaren ledelse som arbeider for komme med behandling til en pasientgruppe der det er lite utvalg medisin.
ODD, fast track, PIM, i en eldre, vanskelig å behandle pasientgruppe skal nok ikke “kimses” av og er viktig å ha i bakhode.
edit: tror vi kommer bra utav det når fasit foreligger tilslutt.
2 Likes
Biotwitter er jo et begrep på samme måte fintwit er det. 
men vil ikke overdrive viktigheten heller
1 Like
Ser ikke bort fra at det har litt verdi i USA spesielt. All PR er god PR. Du er flink å fremme norsk biotek, takker og bukker!
2 Likes